Mental Health TALK SAFE Act of 2026

Bill Number

H.R. 6994

Origin Chamber

House

Congress

119th Congress, Session 2

Policy Area

Health

Status

Introduced

Latest Action

2026-01-09: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Last Updated

2026-01-26T13:34:38Z

AI-Generated Summary

Summary of H.R. 6994: Mental Health TALK SAFE Act of 2026

Purpose

This bill aims to expand access to controlled substances (like certain medications for mental health disorders or opioid use disorder) through telehealth services. It modifies rules under the Controlled Substances Act to allow prescriptions via online evaluations while adding safeguards to prevent misuse, such as strict requirements for telehealth providers and protections against arbitrary refusals by pharmacists. The goal is to support mental health treatment, especially for patients who may lack in-person access.

Key Provisions

• Valid Prescriptions via Telehealth: A prescription for controlled substances is considered valid if issued by a qualified telehealth practitioner (a psychiatrist or specially certified psychiatric-mental health advanced practice nurse) after at least one telehealth evaluation (a remote medical check using audio or video communication). This applies specifically to "approved mental health controlled substances" (FDA-approved drugs in schedules II non-narcotics, III, IV, or V for mental health treatment) and schedule II-V drugs for opioid use disorder.
• Covering Practitioners: A practitioner can issue follow-up prescriptions if they (or a covering provider) have conducted an in-person, telemedicine, or telehealth evaluation within the prior 90 days.
• Telehealth Entity Requirements: Telehealth companies must meet rigorous standards to qualify, including:
• No ownership ties to mail-order-only pharmacies.
• Limits on subscription-based billing and out-of-pocket payments (e.g., no more than 50% of charges paid directly by patients in a 12-month period).
• At least 25% of provider time focused on mental health; minimum employment of full-time staff like psychiatrists; caps on advanced practice nurses (no more than two-thirds of providers).
• Compensation rules to avoid incentives based on prescription volume (no more than 75% of pay tied to evaluations).
• Mandatory full-time roles for a Chief Compliance Officer, Chief Clinical Quality Practitioner (board-certified psychiatrist), and Chief Medical Officer (board-certified psychiatrist).
• Ongoing monitoring for FDA-compliant prescribing and accreditation from a medical education body.
• Exempt Entities: Certain organizations (e.g., federally qualified health centers, hospitals, nonprofits, government agencies) are exempt from some telehealth entity rules.
• Pharmacist Responsibilities: Pharmacists cannot refuse to fill a valid telehealth prescription solely because it was issued remotely. Before refusing on validity grounds, they must contact the patient and prescriber to resolve concerns. Violations carry civil penalties up to $25,000 per incident.
• DEA Registrations: Healthcare providers do not need separate Drug Enforcement Administration (DEA) registrations for each state when prescribing via telehealth. They can use the telehealth entity's address as their business location.
• Interstate Psychiatrist Licensure and Insurance: Licensed psychiatrists in their "primary state" (where they are mainly based and insured) can provide telepsychiatry services in "secondary states" without additional licensing, if state rules are substantially similar. Their malpractice insurance must cover services in secondary states as if provided in the primary state. This applies only to mental health-related telehealth and does not expand the scope of their license.
• Preemption of State Laws: Federal rules override any state laws that block or limit the telehealth activities allowed by this bill.

Significant Changes to Existing Law

• Expands Telehealth Flexibility: Previously, the Controlled Substances Act required in-person exams for most telehealth prescriptions of controlled substances. This bill allows one telehealth evaluation to suffice for initial and follow-up prescriptions in specified cases, repealing outdated telemedicine definitions and special registration rules.
• Reduces Administrative Burdens: Eliminates the need for multi-state DEA registrations for telehealth providers, streamlining cross-state practice.
• Adds Regulatory Safeguards: Introduces detailed criteria for "telehealth entities" to ensure ethical operations, which did not exist before, and mandates pharmacist validation steps to protect against fraud.
• Facilitates Interstate Practice: Creates a pathway for psychiatrists to practice across state lines via telehealth without full relicensing, a change from current state-by-state licensing requirements.

Potential Impacts

• On Government Agencies: The DEA will see reduced registration workloads but increased oversight of telehealth entities for compliance. The Food and Drug Administration (FDA) role in approving mental health drugs remains unchanged but is referenced for prescribing limits.
• On Citizens: Patients with mental health disorders or opioid use disorder gain easier access to remote prescriptions, potentially improving treatment adherence and reducing barriers like travel or shortages of local providers. However, safeguards aim to prevent overprescribing or abuse.
• On International Relations: No direct impacts, as the bill focuses on domestic U.S. telehealth and controlled substances.

Main Stakeholders Affected

• Patients: Individuals seeking mental health or opioid treatment via telehealth, who benefit from expanded access.
• Healthcare Providers: Psychiatrists and psychiatric-mental health nurses, who can prescribe across states more easily but must meet employment and compensation rules.
• Telehealth Companies: Entities providing remote services, required to restructure operations (e.g., hiring specific officers, limiting business models) to qualify.
• Pharmacists and Pharmacies: Must follow new validation protocols; mail-order pharmacies face restrictions on partnerships.
• Government and Nonprofits: Health centers, hospitals, and agencies gain exemptions, easing their telehealth expansion.
• States: Licensing boards may see reduced authority due to federal preemption, potentially standardizing rules nationwide.

Notable Legal, Constitutional, or Political Implications

• Federal Preemption: By overriding conflicting state laws, the bill asserts federal authority over interstate telehealth, which could spark debates on federalism (the balance of power between federal and state governments). States with stricter rules might challenge this in court.
• Public Health vs. Regulation Balance: It promotes mental health access amid ongoing telehealth expansions post-COVID-19, but detailed entity requirements could limit smaller providers, raising concerns about barriers to innovation or equity.
• Enforceability: Civil penalties for pharmacists and compliance mandates for entities strengthen enforcement but may increase litigation over definitions like "substantially similar" licensure.
• No Major Constitutional Issues: Aligns with Congress's commerce clause authority over interstate medical practice and controlled substances, without infringing on free speech or privacy rights. Politically, it reflects bipartisan interest in mental health but could face opposition from states favoring local control.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Dunn, Neal P. [R-FL-2]

Cosponsors (1)

Rep. Bacon, Don [R-NE-2]

Recent Actions

• 2026-01-09: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2026-01-09: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2026-01-09: Introduced in House
• 2026-01-09: Introduced in House

Bill Versions

• Mental Health TALK SAFE Act of 2026 — issued 2026-01-09 — PDF (21 pages)